{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Merck and Moderna report 42 percent lower recurrence-or-death risk in melanoma trial","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://media.wired.com/photos/6adbb6236c5716eb12b3253b/191:100/w_1280,c_limit/vacuna%20melanoma%202275195271.jpg","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/oMiMrG4qpmV6WYs4hOPfQF\" style=\"color:#fff;text-decoration:none;\">Merck and Moderna report 42 percent lower recurrence-or-death risk in melanoma trial</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Merck and Moderna reported that their experimental personalised mRNA vaccine, combined with Pembrolizumab, reduced the risk of melanoma recurrence or death by 42 percent compared with Pembrolizumab al...</p>\n    </blockquote>"}